-
1Academic Journal
Authors: Т. Д. Барболина
Source: Malignant tumours; Том 14, № 3s1 (2024); 26-34 ; Злокачественные опухоли; Том 14, № 3s1 (2024); 26-34 ; 2587-6813 ; 2224-5057
Subject Terms: мезотелиома оболочек яичка, стадирование мезотелиомы, индекс канцероматоза, гипертермическая внутрибрюшинная химиотерапия (HIPEC)
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1344/951; Huang J., Chan S.C., Pang W.S., et al. Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study. J Thorac Oncol 2023;18(6):792-802. https://doi.org/10.1016/j.jtho.2023.01.095; Offin M., Yang S-R., Egger J., et al. Molecular Characterization of Peritoneal Mesotheliomas. J Thorac Oncol 2022;17(3):455-460. https://doi.org/10.1016/j.jtho.2021.09.012; Leblay N., Lepretre F., Le Stang N., et al. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. J Thorac Oncol 2017;12:724-733. https://doi.org/10.1016/j.jtho.2016.12.019; Testa J.R., Cheung M., Pei J., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2012;43(10):1022-1025. https://doi.org/10.1038/ng.912; Valenzuela C.D., Solsky I.B., Erali R.A., et al. Long-term survival in patients treated with cytoreduction and heated intraperitoneal chemotherapy for peritoneal mesothelioma at a single high-volume center. Ann Surg Oncol 2023;30(5):2666-2675. https://doi.org/10.1245/s10434-022-13061-3; Beal E.W., Srinivas S., Shen C., et al. Conditional survival following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: an analysis from the US HIPEC Collaborative. Ann Surg Oncol 2023;30(3):1840-1849. https://doi.org/10.1245/s10434-022-12753-0; Ettinger D.S., Wood D.E., Stevenson J., et al. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Peritoneal. Version 1.2023. Accessed May 1, 2023. To view the most recent version, visit https://www.nccn.org; Kusamura S., Kepenekian V., Villeneuve L., et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2021;47(1):36-59. https://doi.org/10.1016/j.ejso.2020.02.011; Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principle s of management. Boston, MA: Springer; 1996. pp. 359-374.; Yan T.D., Deraco M., Elias D., et al. A novel tumor-node metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117(9):1855-63. https://doi.org/10.1002/cncr.25640; Morris M.C., Cloyd J.M., Hays J., Patel S.H. The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. J Gastrointest Surg 2021;25(1):303-318. https://doi.org/10.1007/s11605-020-04771-8; Sugarbaker P.H., Chang D., Jelinek J.S. In 100 patients with malignant peritoneal mesothelioma, concerning CT features predicted outcome of treatment. Eur J Surg Oncol 2021;47(9):2212-2219. https://doi.org/10.1016/j-ejso.2021.04.012; Sugarbaker P.H., Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 2017;43(7):1228-35. https://doi.org/10.1016/j.ejso.2017.01.009; Nazemi A., Nassiri N., Pearce S., Daneshmand S. Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors. Urology 2019;126:140-144. https://doi.org/10.1016/j.urology.2019.01.009; https://www.malignanttumors.org/jour/article/view/1344
-
2Academic Journal
Authors: А. Е. Калинин, В. Гущин, А. А. Доманский, О. А. Кузнецова, В. А. Шаленков, С. А. Абудеев, Н. А. Козлов, В. А. Колышкин, А. В. Привалов, Е. Г. Рыбаков, М. Г. Абгарян, О. И. Сушков
Source: Malignant tumours; Том 14, № 3s1 (2024); 4-13 ; Злокачественные опухоли; Том 14, № 3s1 (2024); 4-13 ; 2587-6813 ; 2224-5057
Subject Terms: HIPEC, муцинозная опухоль аппендикса, циторедукция, гипертермическая внутрибрюшинная химиотерапия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1341/948; Sugarbaker P.H. Are there curative options to peritoneal carcinomatosis?. Ann Surg 2005;242(5):748–751. https://doi.org/10.1097/00000658-200511000-00023; Smeenk R.M., van Velthuysen M.L., Verwaal V.J., Zoetmulder F.A. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201. https://doi.org/10.1016/j.ejso.2007.04.002; Sugarbaker P.H. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7(1):69–76. https://doi.org/10.1016/S1470-2045(05)70539-8; Циторедуктивная хирургия и периоперационная химиотерапия для лечения опухолей с перитонеальной диссеминаций. Руководство и видеоатлас. Второе издание. Под редакцией Пол Шугабейкер, главный редактор русскоязычного издания Вадим Гущин 2019.; Govaerts K., Lurvink R.J., De Hingh IHJ.T., et al. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 2021;47(1):11–35. https://doi.org/10.1016/j.ejso.2020.02.012; Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol 2020;27(6):1761–1767. https://doi.org/10.1245/s10434-020-08315-x; WHO Classification of Tumours Editorial Board. Digestive system tumours (5th edition). – IARC; Lyon, 2019:35–155.; Carr N.J., Cecil T.D., Mohamed F., et al. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 2016;40(1):14–26.9. https://doi.org/10.1097/PAS.0000000000000535; AJCC Staging https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/ajcc-staging-online/; Umetsu S.E., Kakar S. Staging of appendiceal mucinous neoplasms: challenges and recent updates. Hum Pathol 2023;132:65–76. https://doi.org/10.1016/j.humpath.2022.07.004; National Comprehensive Cancer Network v.5.2024 https://www.nccn.org/guidelines/guidelines-detail?category = 1&id = 1428; Carmignani C.P., Hampton R., Sugarbaker C.E., et al. Utility of CEA and CA 19–9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004;87(4):162–166. https://doi.org/10.1002/jso.20107; Munoz-Zuluaga C.A., King M.C., Diaz-Sarmiento V.S., et al. Defining “Complete Cytoreduction» After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. Ann Surg Oncol 2020 Dec;27(13):5026–5036. doi:10.1245/s10434-020-08844-5, PMID: 32705513.; Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456. https://doi.org/10.1200/JCO.2011.39.7166; Nikiforchin A., Sardi A., King MC., et al. Safety of Nephrectomy Performed During CRS/HIPEC: A Propensity Score-Matched Study. Ann Surg Oncol 2023;30(4):2520–2528. https://doi.org/10.1245/s10434-022-12862-w; Glehen O., Mohamed F., Sugarbaker P.H. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004 Aug;240(2):278–85. https://doi.org/10.1097/01.sla.0000133183.15705.71; Baratti D., Kusamura S., Nonaka D., et al. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249(2):243–249. https://doi.org/10.1097/SLA.0b013e31818eec64; Somashekhar S.P., Rohit K.C., Ramya Y., et al. Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS + HIPEC for Peritoneal Surface Malignancy. Ann Surg Oncol 2022 Jan;29(1):214–223. https://doi.org/10.1245/s10434-021-10661-3; Hübner M., Kusamura S., Villeneuve L., et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol 2020;46(12):2292–2310. https://doi.org/10.1016/j.ejso.2020.07.041; Hübner M., Kusamura S., Villeneuve L., et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part II: Preoperative and intraoperative management. Eur J Surg Oncol 2020;46(12):2311–2323. https://doi.org/10.1016/j.ejso.2020.08.006; Solanki S.L., Mukherjee S., Agarwal V., et al. Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Indian J Anaesth 2019;63(12):972–987. https://doi.org/10.4103/ija.IJA_765_19; Lopez-Ramirez F., Gushchin V., Sittig M., et al. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol 2022;29(6):3390–3401. https://doi.org/10.1245/s10434-021-11233-1; Bhutiani N., Grotz T.E., Concors S.J., et al. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol 2024;31(1):614–621. https://doi.org/1010.1245/s10434-023-14422-2; Blackham A.U., Swett K., Eng C., et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2014;109(7):740–745. https://doi.org/10.1002/jso.23547; Asare E.A., Compton C.C., Hanna N.N., et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer 2016;122(2):213–221. https://doi.org/10.1002/cncr.29744; Milovanov V., Sardi A., Ledakis P., et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol 2015;41(5):707–712. https://doi.org/10.1016/j.ejso.2015.01.005; Pietrantonio F., Maggi C., Fanetti G., et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 2014;19(8):845–850. https://doi.org/10.1634/theoncologist.2014-0106; Baron E., Sardi A., King M.C., et al. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2023;49(1):179–187. https://doi.org/10.1016/j.ejso.2022.08.022; Tejani M.A., ter Veer A., Milne D., et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw 2014;12(8):1123–1130. https://doi.org/10.6004/jnccn.2014.0109; Baron E., King M.C., Gushchin V., et al. ASO Author Reflections: CRS/HIPEC Cannot be Done-Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer. Ann Surg Oncol 2022;29(11):6590–6591. https://doi.org/10.1245/s10434-022-11925-2; Logan-Collins J.M., Lowy A.M., Robinson-Smith T.M., et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008;15(3):738–744. https://doi.org/10.1245/s10434-007-9699-7; Choe J.H., Overman M.J., Fournier K.F., et al. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 2015;22(8):2578–2584. https://doi.org/10.1245/s10434-014-4335-9; Franke A.J., Iqbal A., Starr J., et al. Management of malignant bowel obstruction associated with gi cancers. J Oncol Pract 2017;13(7):426–434. https://doi.org/10.1200/jop.2017.022210.; https://www.malignanttumors.org/jour/article/view/1341
-
3Academic Journal
Authors: Nazarov, Ya.S., Kopetskyi, V.I., Shudrak, Ye.A.
Source: Практична онкологія-Praktična onkologìâ; Том 3, № 2 (2020); 18-25
Practical oncology; Том 3, № 2 (2020); 18-25
Практическая онкология-Praktična onkologìâ; Том 3, № 2 (2020); 18-25Subject Terms: рак яєчника, рак яєчника III–IV стадії, циторедуктивна хірургія, циторедукція, гіпертермічна внутрішньочеревна хіміотерапія, огляд, ovarian cancer, stage III–IV ovarian cancer, cytoreductive surgery, debulking, hyperthermic intraperitoneal chemotherapy, review, 0103 physical sciences, рак яичника, рак яичника III–IV стадии, циторедуктивная хирургия, циторедукция, гипертермическая внутрибрюшинная химиотерапия, обзор, 01 natural sciences, 3. Good health
File Description: application/pdf
-
4Academic Journal
Authors: Ya. G. Murazov, A. L. Semenov, K. Yu. Senchik, A. O. Nyuganen, A. S. Artemyeva, A. M. Belyaev, Я. Г. Муразов, А. Л. Семенов, К. Ю. Сенчик, А. О. Нюганен, А. С. Артемьева, А. М. Беляев
Source: Siberian journal of oncology; Том 20, № 6 (2021); 78-87 ; Сибирский онкологический журнал; Том 20, № 6 (2021); 78-87 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-6
Subject Terms: доклинические исследования, peritoneal carcinomatosis, intraperitoneal chemotherapy, Hipec, cisplatin, preclinical trials, перитонеальный канцероматоз, внутрибрюшинная химиотерапия, цисплатин
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1989/933; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul; 70(4): 313]. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.; Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr; 11: 287–99. doi:10.2147/IJWH.S197604.; van Baal J.O.A.M., van Noorden C.J.F., Nieuwland R., Van de Vijver K.K., Sturk A., van Driel W.J., Kenter G.G., Lok C.A.R. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J Histochem Cytochem. 2018 Feb; 66(2): 67–83. doi:10.1369/0022155417742897.; Helderman R.F.C.P.A., Löke D.R., Kok H.P., Oei A.L., Tanis P.J., Franken N.A.P.K., Crezee J. Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers (Basel). 2019 Jan; 11(1): 78. doi:10.3390/cancers11010078.; van Driel W.J., Koole S.N., Sikorska K., Schagen van Leeuwen J.H., Schreuder H.W.R., Hermans R.H.M., de Hingh I.H.J.T., van der Velden J., Arts H.J., Massuger L.F.A.G., Aalbers A.G.J., Verwaal V.J., Kieffer J.M., Van de Vijver K.K., van Tinteren H., Aaronson N.K., Sonke G.S. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan; 378(3): 230–40. doi:10.1056/NEJMoa1708618.; Sticca R.P., Dach B.W. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003 Jul; 12(3): 689–701. doi:10.1016/s1055-3207(03)00029-2.; Погосянц Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая асцитная опухоль яичника крысы (штамм ОЯ). Вопросы онкологии. 1962; 8(11): 29–36.; Klaver Y.L., Hendriks T., Lomme R.M., Rutten H.J., Bleichrodt R.P., de Hingh I.H. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model. Br J Surg. 2010 Dec; 97(12): 1874–80. doi:10.1002/bjs.7249.; Schoenfeld D.A., Richter J.R. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982 Mar; 38(1): 163–70.; Goodman M.D., McPartland S., Detelich D., Saif M.W. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016 Feb; 7(1): 45–57. doi:10.3978/j.issn.2078-6891.2015.111.; Sugarbaker P.H., Graves T., DeBruijn E.A., Cunliffe W.J., Mullins R.E., Hull W.E., Oliff L., Schlag P. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990 Sep; 50(18): 5790–4.; González-Moreno S., González-Bayón L.A., Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010 Feb; 2(2): 68–75. doi:10.4251/wjgo.v2.i2.68.; McCabe-Lankford E., Peterson M., McCarthy B., Brown A.J., Terry B., Galarza-Paez L., Levi-Polyachenko N. Murine Models of Intraperitoneal Perfusion for Disseminated Colorectal Cancer. J Surg Res. 2019 Jan; 233: 310-322. doi:10.1016/j.jss.2018.07.063.; Harris S.J., Brown J., Lopez J., Yap T.A. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016 Jun; 13(2): 171–93. doi:10.20892/j.issn.2095-3941.2016.0015.; Zunino B., Rubio-Patiño C., Villa E., Meynet O., Proics E., Cornille A., Pommier S., Mondragón L., Chiche J., Bereder J.M., Carles M., Ricci J.E. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016 Jan; 35(2): 261–8. doi:10.1038/onc.2015.82.; Skitzki J.J., Repasky E.A., Evans S.S. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 2009 Jun; 10(6): 550–8.; https://www.siboncoj.ru/jour/article/view/1989
-
5Academic Journal
Authors: Д. Д. Мориков, А. В. Шелехов, Владимир Ильич Горбачев, В. В. Дворниченко, А. Г. Павлов, С. И. Радостев
Source: Вестник интенсивной терапии, Iss 3 (2021)
Subject Terms: рак яичников, анестезиологическое пособие, циторедуктивная хирургия, гипертермическая внутрибрюшинная химиотерапия, инфузионно-трансфузионная терапия, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
File Description: electronic resource
-
6Academic Journal
Authors: Sh. Kh. Gantsev, M. V. Zabelin, K. Sh. Gantsev, A. A. Izmailov, Sh. R. Kzyrgalin, Ш. Х. Ганцев, М. В. Забелин, К. Ш. Ганцев, А. А. Измайлов, Ш. Р. Кзыргалин
Source: Creative surgery and oncology; Том 11, № 1 (2021); 85-91 ; Креативная хирургия и онкология; Том 11, № 1 (2021); 85-91 ; 2076-3093 ; 2307-0501
Subject Terms: научные школы, cytoreductive surgery, systemic chemotherapy, hyperthermic intraperitoneal chemotherapy, school of thought, циторедуктивная хирургия, системная химиотерапия, гипертермическая внутрибрюшинная химиотерапия
File Description: application/pdf
Relation: https://www.surgonco.ru/jour/article/view/575/442; Ганцев Ш.Х., Соломенный С.В., Ганцев К.Ш., Кзыргалин Ш.Р., Минигазимов Р.С., Логинова М.В. Оценка состояния серознолимфатических люков при перитонеальном канцероматозе по данным сканирующей электронной микроскопии (на примере диафрагмальной брюшины). Креативная хирургия и онкология. 2014;(4):4–10. DOI:10.24060/2076-3093-2014-0-4-4-10; Sugarbaker P.H., Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107. DOI:10.1159/000012086; Cotte E., Passot G., Gilly F.N., Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2(1):31–5. DOI:10.4251/wjgo.v2.i1.31; Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. DOI:10.1002/(sici)1097-0142(20000115)88:23.0.co;2-o; European School of Peritoneal Surface Oncology (ESPSO). [cited 2020 Dec 20]. Available from: http://www.essoweb.org/school-of-peritonealsurface-oncology-es/; Sugarbaker P.H., Chang D., Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:89–104. DOI:10.1007/978-1-4613-1245-1_9; Sugarbaker P.H., Stuart O.A. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. Surg Oncol. 2020;33:96–9. DOI:10.1016/j.suronc.2020.01.009; Sugarbaker P.H. Intraperitoneal delivery of chemotherapeutic agents for the treatment ofperitoneal metastases: current challenges and how to overcome them. Expert Opin Drug Deliv. 2019;16(12):1393–401. DOI:10.1080/17425247.2019.1693997; Carr N.J., Bibeau F., Bradley R.F., Dartigues P., Feakins R.M., Geisinger K.R., et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–58. DOI:10.1111/his.13324; Nors J., Funder J.A., Swain D.R., Verwaal V.J., Cecil T., Laurberg S., et al. Postoperative paralytic ileus after cytoreductive surgery combined with heated intraperitoneal chemotherapy. Pleura Peritoneum. 2019;5(1):20190026. DOI:10.1515/pp-2019-0026; Farquharson M., Hollingshead J., Brendan M. (eds). Farquharson’s Textbook of Operative General Surgery. 10th ed. CRC Press; 2014.; Brendan M., Heald R.J. (editors) Manual of Total Mesorectal Excision. CRC Press; 2013.; Canbay E., Yonemura Y. Peritoneal Surface Malignancies: A Curative Approach. 10th ed. Springer; 2015.; Ji Z.H., Peng K.W., Yu Y., Li X.B., Yonemura Y., Liu Y., et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–70. DOI:10.1080/02656736.2017.1283065; Coccolini F., Nardi M., Montori G., Ceresoli M., Celotti A., Cascinu S., et al. Neoadjuvant chemotherapyin advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120–7. DOI:10.1016/j.ijsu.2018.01.008; Lin Y.L., Zhang J., Yan F.C., Jiang X., Ma R., Yang Z.R., et al. Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil. Cancer Med. 2020;9(3):1104–14. DOI:10.1002/cam4.2766; Yang X.J., Huang C.Q., Suo T., Mei L.J., Yang GL., Cheng F.L., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81. DOI:10.1245/s10434-011-1631-5; Huang C.Q., Min Y., Wang S.Y., Yang X.J., Liu Y., Xiong B., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of currentevidence. Oncotarget. 2017;8(33):55657–83. DOI:10.18632/oncotarget.17497; Guadagni S., Clementi M., Masedu F., Fiorentini G., Sarti D., Deraco M., et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer. Int J Mol Sci. 2020;21(13):4813. DOI:10.3390/ijms21134813; Belfiore A., Busico A., Bozzi F., Brich S., Dallera E., Conca E., et al. Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma. Int J Mol Sci. 2019;20(22):5817. DOI:10.3390/ijms20225817; Glehen O., Gilly F.N. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71. DOI:10.1016/s1055-3207(03)00037-1; Alyami M., Hübner M., Grass F., Bakrin N., Villeneuve L., Laplace N., et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77. DOI:10.1016/S1470-2045(19)30318-3; Glehen O., Osinsky D., Beaujard A.C., Gilly F.N. Natural history of peritoneal carcinomatosis from non gynecologic malignancies. Surg Oncol Clin N Am. 2003;12(3):729–39, XIII. DOI:10.1016/s1055-3207(03)00044-9; Glehen O., Gilly F.N., Cotte E. Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism? Ann Surg Oncol. 2011;18(6):1524–6. DOI:10.1245/s10434-011-1632-4; Rau B., Brandl A., Piso P., Pelz J., Busch P., Demtröder C., et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11–22. DOI:10.1007/s10120-019-00978-0; Vassos N., Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. DOI:10.1007/s11864-018-0563-8; https://www.surgonco.ru/jour/article/view/575
-
7Academic Journal
Source: Креативная хирургия и онкология, Vol 11, Iss 2, Pp 149-156 (2021)
Subject Terms: злокачественные новообразования, перитонеальный канцероматоз, циторедуктивная хирургия, системная химиотерапия, гипертермическая внутрибрюшинная химиотерапия, перитонеальные метастазы, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Relation: https://www.surgonco.ru/jour/article/view/585; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/96fe1f82d0d04dd9afcc3694854300e6
-
8
-
9Academic Journal
Authors: D. D. Morikov, A. V. Shelekhov, V. I. Gorbachev, V. V. Dvornichenko, A. G. Pavlov, S. I. Radostev, I. I. Osadchiy, T. G. Zyabreva, Д. Д. Мориков, А. В. Шелехов, В. И. Горбачев, В. В. Дворниченко, А. Г. Павлов, С. И. Радостев, И. И. Осадчий, Т. Г. Зябрева
Source: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 16, № 5 (2019); 24-30 ; Вестник анестезиологии и реаниматологии; Том 16, № 5 (2019); 24-30 ; 2541-8653 ; 2078-5658
Subject Terms: гипертермическая внутрибрюшинная химиотерапия, anesthetic aid, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, анестезиологическое пособие, циторедуктивная хирургия
File Description: application/pdf
Relation: https://www.vair-journal.com/jour/article/view/372/382; Аксель Е. М., Виноградова Н. Н. Статистика злокачественных новообразований женских репродуктивных органов // Онкогинекология. ‒ 2018. ‒ № 3. ‒ С. 64‒78.; Смешной И. А., Пасечник И. Н., Скобелев Е. И. и др. Оптимизация инфузионной терапии в плановой абдоминальной хирургии // Общая реаниматология. ‒ 2018. ‒ Т. 14, № 5. ‒ С. 4‒15.; Химиоперфузионное лечение злокачественных опухолей. Руководство для врачей / под ред. Беляева А. М., Леонтьева О. В., Рогачева М. В. ‒ СПб.: СпецЛит, 2018. ‒ 286 с.; Хороненко В. Э., Шеметова М. М., Дрожжина О. В. и др. Анестезиологическое обеспечение и интенсивная терапия при проведении гипертермической интраоперационной внутрибрюшной химиотерапии у больных раком желудка. Обзор литературы и собственный клинический опыт // Анестезиология и реаниматология. ‒ 2015. ‒ Т. 60, № 1. ‒ С. 50‒54.; Шелехов А. В., Дворниченко В. В., Радостев С. И. и др. Опыт применения технологии циторедуктивной хирургии с методом интраоперационной интраперитонеальной гипертермической химиотерапии в лечении больных распространенным раком яичников // Сибирский онкологический журнал. ‒ 2018. ‒ Т. 17, № 3. ‒ С. 58‒63.; Bakrin N., Classe J. M., Pomel C. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer // J. Visc. Surg. ‒ 2014. ‒ Vol. 151, № 5. ‒ P. 347‒353.; Cata J. P., Zavala A. M., Van Meter A. et al. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study // Intern. J. Hyperthermia. ‒ 2018. ‒ Vol. 34, № 5. ‒ P. 538‒544.; Colantonio L., Claroni C., Fabrizi L. et al. A randomized trial of goal direct vs standart fluid therapy in cytoreductive surgery with hiperthermic intraperitoneal chemotherapy // J. Gastrointest. Surg. ‒ 2015. ‒ № 19. ‒ P. 722.; De Brito Poveda V., Clark A. M., Galvão C. M. A systematic review on the effectiveness of prewarming to prevent perioperative hypothermia // J. Clin. Nurs. ‒ 2013. ‒ Vol. 22, № 7‒8. ‒ P. 906‒918.; Esteve-Perez N., Ferrer-Robles A., Gomez-Romero G. et al. Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study // Clin. Transl. Oncol. ‒ 2018. ‒ https://doi.org/10/1007/s12094-018-1944- (First Online: 14 September 2018).; Iavazzo C., Spiliotis J. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a "useless intraoperative fever" or the next hot voice in the surgical management of the "silent killer"? // Arch. Gynecol. Obstet. ‒ 2018. ‒ Vol. 298, № 4. ‒ P. 673‒674.; I-Lin E. S., Shulyn C. C., Hwei Ching G. T. et al. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy // Intern. J. Hyperthermia. ‒ 2017. ‒ Vol. 33, № 6. ‒ P. 690‒695.; Morales-Soriano R., Esteve-Perez N., Segura-Sampedro J. J. et al. Spanish Group of Peritoneal Malignancy Surface (GECOP). Current practice in cytoreductive surgery and HIPEG for metastatic peritoneal disease: Spanish multicentric survey // Eur. J. Surg. Oncology. ‒ 2018. ‒ Vol. 44, Issue 2. ‒ P. 228‒236.; Raspe C., Fletcher L., Schneider R. et al. Best practice for perioperative management of patients with cytoreductive surgery and HIPEG // Eur. J. Surg. Oncology. ‒ 2017. ‒ Vol. 43, Issue 6. ‒ P. 1013‒1027. https://doi.org/10.1016/j.ejso.2016.19.008; Sugarbaker P. H. Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? // Am. J. Surg. ‒ 2011. ‒ Vol. 201. ‒ P. 157–159.
-
10Academic Journal
Authors: A. A. Rumyantsev, A. S. Tjulandina, I. A. Pokataev, S. A. Tjulandin, А. А. Румянцев, А С. Тюляндина, И. А. Покатаев, С. А. Тюляндин
Source: Malignant tumours; № 3 (2017); 13-22 ; Злокачественные опухоли; № 3 (2017); 13-22 ; 2587-6813 ; 2224-5057
Subject Terms: внутрибрюшинная химиотерапия, surgical treatment, primary debulking, interval debulking, chemotherapy, intraperitoneal chemotherapy, хирургическое лечение, первичная циторедукция, интервальная циторедукция, неоадъювантная химиотерапия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/387/333; Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные заболевания в России в 2014 году (заболеваемость и смертность). М., 2016. 250 с. [Kaprin A. D., Starinskii V. V., Petrova G. V. Zlokachestvennye zabolevaniya v Rossii v 2014 godu (zabolevaemost’i smertnost’), Moscow, 2016, 250 p. (In Russ.)].; Howlader N., Noone A. M., Krapcho M. et al. SEER Cancer Statistics Review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.; Griffiths C. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma, Natl. Cancer Inst. Monogr., 1975, Vol. 42, pp. 101–104.; Hoskins W. J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol. Oncol., 1994, Vol. 55 (3 Pt. 2), pp. S91–S96.; Elattar A., Bryant A., Winter-Roach B. A., Hatem M., Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev., 2011, Issue 8, Art. No. CD007565.; Winter W. E. 3rd, Maxell G. L., Tian C., Carlson J. W., Ozols R. F., Rose P. G. et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study, J. Clin. Oncol., 2007, Vol. 25 (24), pp. 3621–3627.; du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials, Cancer, 2009, Vol. 115 (6), pp. 1234–1244.; Crawford S. C., Vasey P. A., Paul J., Hay A., Davis J. A., Kaye S. B. Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial, J. Clin. Oncol., 2005, Vol. 34; pp. 8802–8811.; Horowitz N. S., Miller A., Rungruang B., Richard S. D., Rodriguez N., Bookman M. A. et al. Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182, J. Clin. Oncol., 2015, Vol. 8, pp. 937–943.; Bookman M. A., Brady M. F., McGuire W. P., Harper P. G., Alberts D. S., Friedlander M. et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup, J. Clin. Oncol., 2009, Vol. 9, pp. 1419–1425.; Chi D. S., Eisenhauer E. L., Zivanovic O., Sonoda Y., Abu-Rustum N. R., Levine D. A. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm, Gynecol. Oncol., 2009, Vol. 114 (1), pp. 26–31.; Harter P., Muallem Z. M., Buhrmann C., Lorenz D., Kaub C., Hils R. et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer, Gynecol. Oncol., 2011, Vol. 121 (3), pp. 615–619.; Vergote I., Trope C. G, Amant F., Kristensen G. B., Ehlen T., Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 2010, Vol. 363, pp. 943–953.; Vergote I., Trope C. G., Amant F., Kristensen G. B., Ehlen T., Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N. Engl. J. Med., 2010, Vol. 363, pp. 943–953, Supplementary appendix.; Kehoe S., Hook J., Nankivell M., Jayson G. C., Kitchener H., Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 2015, Vol. 386, pp. 249–257.; Kehoe S., Hook J., Nankivell M., Jayson G. C., Kitchener H., Lopes T. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet, 2015, Vol. 386, pp. 249–257, Supplementary appendix.; Chi D. S., Musa F., Dao F., Zivanovic O., Sonoda Y., Leitao M. M. et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT), Gynecol. Oncol., 2012, Vol. 124 (1), pp. 10–14.; Tanner E.J., Long K.C., Feffer J.B., Leitao M.M. Jr, Abu-Rustum N.R., Barakat R.R. et al. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer, Gynecol. Oncol., 2013, Vol. 128 (1), pp. 28–33.; Pairetti M., Zanagnolo V., Aletti G. D., Bocciolone L., Colombo N., Landoni F. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubalcancer: Surgical and oncological outcomes. Single institution experience, Gynecol. Oncol., 2010, Vol. 119 (2), pp. 259–264.; Oza A. M., Cook A. D., Pfisterer J., Embleton A., Ledermann J. A., Pujade-Lauraine E. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol., 2015, Vol. 16 (8), pp. 928–936.; van der Burg M. E., van Lent M., Buyse M., Kobierska A., Colombo N., Favall G. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N. Engl. J. Med., 1995, Vol. 332 (10), pp. 629–634.; Onda T., Satoh T., Saito T., Kasamatsu T., Nakanishi T., Nakamura K. et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III / IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602, Eur. J. Cancer, 2016, Vol. 64, pp. 22–31.; Luo Y., Lee M., Kim H. S., Chung H. H., Song Y. S. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer, Medicine (Baltimore), 2016, Vol. 95 (36), e4797.; Rauh-Hain J. A., Nitschmann C. C., Worley M. J. Jr, Bradford L. S., Berkowitz R. S., Schorge J. O. et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma, Gynecol. Oncol., 2013, Vol. 129 (1), pp. 63–68.; Melamed A., Hinchcliff E. M., Clemmer J. T., Bregar A. J., Uppal S., Bostock I. et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States, Gynecol. Oncol., 2016, Vol. 143 (2), pp. 236–240.; Meyer L. A., Sronin A. M., Sun C. C., Bixel K., Bookman M. A., Cristea M. C. et al. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer, J. Clin. Oncol., 2016, Vol. 32, pp. 3854–3863.; Narod S., Sopik V. Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted? Gynecol. Oncol., 2017, Vol. 144 (2), pp. 238–240.; Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S. et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer, N. Engl. J. Med., 2006, Vol. 354, pp. 34–43.; Landrum L. M., Java J., Mathews C. A., Lanneau G. S. Jr, Copeland L. J., Armstrong D. K. et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study, Gynecol. Oncol., 2013, Vol. 130 (1), pp. 12–18.; Mueller J. J., Kelly A., Zhou Q., Iasonos A., Long Roche K., Sonoda Y. et al. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center, Gynecol. Oncol., 2016, Sep 28 [Epub ahead of print].; https://www.malignanttumors.org/jour/article/view/387
-
11Academic Journal
Authors: КЕДРОВА А.Г., ЛЕВАКОВ С.А., КРАСИЛЬНИКОВ С.Э., МАКСИМЕНКО Т.А., ВОЗНЕСЕНСКИЙ В.И., ГЕРАСИМОВ А.В., АСТАХОВ Д.А., КОСЫЙ В.В., НЕЧАЕВА О.Е.
File Description: text/html
-
12Academic Journal
Source: Опухоли женской репродуктивной системы.
Subject Terms: РАК ЯИЧНИКОВ,ВНУТРИБРЮШИННЫЕ МЕТАСТАЗЫ,ВНУТРИБРЮШИННАЯ ХИМИОТЕРАПИЯ,ОПТИМАЛЬНАЯ ЦИТОРЕДУКТИВНАЯ ОПЕРАЦИЯ,СЕРОЗНАЯ АДЕНОКАРЦИНОМА ЯИЧНИКОВ ВЫСОКОЙ СТЕПЕНИ ЗЛОКАЧЕСТВЕННОСТИ,СЕРОЗНАЯ АДЕНОКАРЦИНОМА ЯИЧНИКОВ НИЗКОЙ СТЕПЕНИ ЗЛОКАЧЕСТВЕННОСТИ,ЦИСПЛАТИН,ПАКЛИТАКСЕЛ,ПОРТ-СИСТЕМЫ CELSITE®, 3. Good health
File Description: text/html
-
13Academic Journal
Authors: Тюляндина, А., Буйденок, В., Жорданиа, К., Паниченко, И., Кузнецов, В., Стенина, М., Тюляндин, С.
Subject Terms: РАК ЯИЧНИКОВ, ВНУТРИБРЮШИННАЯ ХИМИОТЕРАПИЯ, ПАКЛИТАКСЕЛ, ЦИСПЛАТИН
File Description: text/html
-
14Academic Journal
Authors: Рухляда, Николай, Бирюкова, Елена, Аракелян, Бюзанд
File Description: text/html
-
15Academic Journal
Source: Опухоли женской репродуктивной системы.
File Description: text/html
-
16Academic Journal
Source: Журнал акушерства и женских болезней.
Subject Terms: ЭНДОМЕТРИОЗ, ВНУТРИБРЮШИННАЯ ХИМИОТЕРАПИЯ, АГОНИСТЫ ГОДАНОТРОПИН-РЕЛИЗИНГ ГОРМОНА, 3. Good health
File Description: text/html
